Boundless Bio, Inc.

NASDAQ: BOLD · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001782303Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 45DQ —GM —SS 50

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, balance-sheet leverage · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$58.2M

Employees

as of 2026-08-19

Market cap

$64.3M

as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$58.2M-$58.2M2025

Operating income-$63.6M-$63.6M2025

Total assets$157.1M$157.1M2025

Liabilities$58.4M$58.4M2025

Equity$98.7M$98.7M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Boundless Bio, Inc.’s financial profile?

Boundless Bio, Inc. earned -$58.2M in FY2025 net income.

Peers · Healthcare

OS Therapies Incorporated——Citius Oncology, Inc.——Atlantic International Corp——MindWalk Holdings Corp.——MiNK Therapeutics, Inc.——BioStem Technologies, Inc.——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEOZachary Hornby

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: BOLD

Employees28

IPO date2016-07-20

Latest filings

8-K2026-08-28 10-Q2026-08-07 8-K2026-06-23 8-K2026-06-17 8-K2026-05-08 10-Q2026-05-08 DEF 14A2026-04-28 8-K2026-04-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.